Mounjaro dosage: what the label actually says

Who does the label cover, and who does it not?

Patients aged 10 and older with type 2 diabetes are covered, on the same step pattern, with a ceiling of 10 mg rather than 15 mg. The label says the KwikPen is not meant for young patients to inject themselves, and that nothing has been established below age 10.

The Mounjaro label covers neither weight loss nor sleep apnea. Its trials measured weight change, but that is not what the label approves it for.

What if a week gets missed?

The label says a missed dose can be given within 4 days, which is 96 hours. Past 4 days it says to skip that week and go back to the usual day.

The label allows the weekly day to move as long as two doses stay at least 3 days, or 72 hours, apart.

What does it come in?

The device matters for dosing, because some of these hold one dose and some hold four.

Mounjaro and Zepbound are the same drug. So why are the doses different?

Zepbound is the same drug substance from the same manufacturer, approved for weight and sleep apnea rather than blood sugar, and it names 5, 10 and 15 mg as the doses to settle on.

Both products contain tirzepatide, and both come from Eli Lilly and Company. They were approved under separate applications, NDA 215866 and NDA 217806, for different groups of people. A separate application means a separate schedule, a separate top dose and a separate rule for a missed week.

The practical version: Mounjaro stops at 15 mg and Zepbound stops at 15 mg. Neither label sets a dose for the other one’s patients.

Both labels print 2.5, 5, 7.5, 10, 12.5 and 15 mg. Those are the same amounts of tirzepatide on either label. What changes is where each one sits. 7.5 and 12.5 mg are doses you can stay on with Mounjaro, and only steps on Zepbound.

The Zepbound dose schedule in fullMounjaro vs Ozempic compared line by lineMounjaro vs Zepbound compared line by lineWegovy vs Mounjaro compared line by line

How long does it take to reach the 15 mg dose?

Week 21 at the earliest, from the label’s four-week minimum at each of the 5 steps.

Mounjaro has 5 steps between the 2.5 mg start and the 15 mg ceiling. The label asks for at least four weeks on a dose before the next one. Four weeks at each step is where week 21 comes from.

The label does not print week numbers for Mounjaro. It gives the first four weeks, and then the four-week rule. Week 21 is that rule applied step by step, not a number quoted off the page.

Week 21 is a floor, not a schedule. Nothing in the label says a person has to keep climbing, and a slower rise is a decision for whoever wrote the prescription.

Can you stay on a low dose of Mounjaro?

The Mounjaro label names no maintenance dosages at all, so it does not answer this.

The Mounjaro label sets out a way to move up rather than a place to stop. It gives the 2.5 mg start, a step size, and the four-week interval between steps.

That silence is the finding, and it is unusual. Most labels in this class name the doses to settle on. This one describes a rule for moving up instead.

2.5 mg is marked on the ladder as a step rather than a destination.

How does the Mounjaro ladder compare with every other GLP-1 brand?

Mounjaro tops out at 15 mg once a week. Eight brands in this class stop in eight different places.

The table below compares the approved GLP-1 brands by their highest labeled dose. It is the only place the eight ladders are set out together.

Milligrams do not carry across molecules. 15 mg of tirzepatide is not comparable to 15 mg of anything else. The last column says so on every row where the drug substance differs.

Where two brands do share a drug substance, the comparison is real, because the same molecule is being measured. That is the case for exactly two pairs in the class.

Do the side effects change as the dose goes up?

The label does not publish side effects broken out by dose for Mounjaro. It reports them across a whole trial.

This is the question the trial tables cannot answer. A label counts how many people reported something over a study, not which dose they were on that week.

The escalation itself is the closest thing to an answer the label gives. It exists because moving up slowly is how the trials were run. The four-week interval is part of the approved schedule, not advice added later.

Where a figure does exist it sits on the side-effect page for this brand. It is taken from the label’s own trial table, with the arm it belongs to.

What is the most important information I should know about Mounjaro?

The label’s boxed warning covers thyroid tumors in rodents

Like every drug in this family, Mounjaro opens with a boxed warning drawn from rat studies that found thyroid C-cell tumors. The human risk is unknown. Anyone with medullary thyroid cancer in the family, or with the inherited condition MEN 2, is ruled out by the label.

A boxed warning is the strongest warning the FDA applies. It appears at the top of the label, before the dosing section summarized here.

It does not change with the dose. Nothing on the ladder above makes it apply more or less.

Do not use Mounjaro if:

The label’s boxed warning names the histories it says rule the drug out, and they are not dose-related.

The exclusions sit in the boxed warning rather than in the dosing section. They are about who a person is, not about how many milligrams they take.

The label separately lists 8 serious effects it tells prescribers to watch for. Each one is set out with the label’s own wording on the Mounjaro side-effect page.

The dose schedule comes from the prescribing label. Read the full label for the complete list of reasons not to take it.

What are the possible side effects of Mounjaro?

The most common in the label’s own trial table is nausea, reported by 18% on Mounjaro 15 mg.

That figure comes from the label’s trial table, with the arm it belongs to attached. A percentage without its arm is not a rate of anything.

The trial reports side effects across the whole study. It does not say which dose each person was taking, so effects cannot be split by dose step.

The full table, every arm and the placebo column beside it, sits on the Mounjaro side-effect page.

Where to read next

4 pages sit next to this one, and each answers something this page deliberately does not.

• Mounjaro side effects, dose by dose carries the label’s own trial table.
• The tirzepatide dosage chart covers the drug rather than the brand, including the vial and syringe arithmetic no pen needs.
• Storing Mounjaro safely covers the fridge, the room-temperature window and what the label leaves out.
• What Mounjaro costs reads the price off the manufacturer’s own terms rather than the label, including who those terms shut out.